HALO · Nasdaq · CIK 0001159036

HALOZYME THERAPEUTICS, INC.

HALOZYME THERAPEUTICS, INC.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 8, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $1.4B and net income of $316.9M, according to its XBRL data on EDGAR. Its EDGAR record lists 50 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$1.4B
Net income, FY2025
$316.9M
Form 4 filings on record, past 12 months
50

Company overview

Legal name (as filed)
HALOZYME THERAPEUTICS, INC.
Ticker
HALO
SEC Central Index Key (CIK)
0001159036
Business address
SAN DIEGO, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#736 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from HALOZYME THERAPEUTICS, INC.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$443.3MFY2021$660.1MFY2022$829.3MFY2023$1.0BFY2024$1.4BFY2025
Net income
$402.7MFY2021$202.1MFY2022$281.6MFY2023$444.1MFY2024$316.9MFY2025
HALO annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$443.3M$660.1M$829.3M$1.0B$1.4B
Net income$402.7M$202.1M$281.6M$444.1M$316.9M
Diluted EPS$2.74$1.44$2.10$3.43$2.56
Total assets$1.1B$1.8B$1.7B$2.1B$2.5B
Cash and equivalents$118.7M$234.2M$118.4M$115.8M$133.8M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

HALO latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 17, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Sep 30, 20268-KDirector or officer change· period Sep 28, 2026Document · Index
Mar 23, 2026DEF 14ADefinitive proxy statement· period Dec 31, 2025Document · Index

Recent SEC filings

The 40 newest documents filed by or about HALOZYME THERAPEUTICS, INC., by form type:

4 ×198-K ×8144 ×73 ×310-Q ×24/A ×1
HALO recent filings
FiledFormWhat it isOriginal
Oct 8, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 6, 2026Document · Index
Oct 8, 20264/AStatement of changes in beneficial ownership (insider trade)· period May 5, 2026Document · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Oct 2, 20263Initial statement of beneficial ownership· period Sep 28, 2026Document · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Sep 30, 20268-KDirector or officer change· period Sep 28, 2026Document · Index
Sep 22, 20268-KMaterial agreement; New financial obligation; Unregistered equity sale· period Sep 22, 2026Document · Index
Sep 18, 20268-KOther events· period Sep 17, 2026Document · Index
Sep 17, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 16, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 16, 20268-KOther events· period Sep 16, 2026Document · Index
Sep 11, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 9, 2026Document · Index
Sep 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 1, 2026Document · Index
Aug 21, 20263Initial statement of beneficial ownership· period Aug 14, 2026Document · Index
Aug 19, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 17, 2026Document · Index
Aug 18, 20268-KDirector or officer change· period Aug 14, 2026Document · Index
Aug 17, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 11, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 11, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 10, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 6, 20268-KResults of operations· period Aug 6, 2026Document · Index
Jul 9, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 8, 2026Document · Index
Jul 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 30, 2026Document · Index
Jul 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 1, 2026Document · Index
Jul 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 1, 2026Document · Index
Jul 2, 20268-KDirector or officer change· period Jun 30, 2026Document · Index
Jun 30, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 29, 2026Document · Index
Jun 29, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 12, 2026Document · Index
Jun 9, 20263Initial statement of beneficial ownership· period Jun 8, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
Jun 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
May 15, 2026144Notice of proposed sale of securitiesDocument · Index
May 13, 20264Statement of changes in beneficial ownership (insider trade)· period May 11, 2026Document · Index
May 11, 2026144Notice of proposed sale of securitiesDocument · Index
May 11, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 11, 20268-KResults of operations· period May 11, 2026Document · Index
May 7, 20264Statement of changes in beneficial ownership (insider trade)· period May 5, 2026Document · Index
May 7, 20264Statement of changes in beneficial ownership (insider trade)· period May 5, 2026Document · Index

Insider filing activity

50 Form 4 filings appear in HALOZYME THERAPEUTICS, INC.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Biological Products, (No Diagnostic Substances)

All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001159036 and XBRL company facts. HALOZYME THERAPEUTICS, INC. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.